Modern capaibilities of pathogenetic drug therapy of tuberculosis
https://doi.org/10.18093/0869-0189-2025-35-5-714-722
Abstract
The problem of multidrug resistant pathogens has significantly limited the capabilities of tuberculosis chemotherapy, reinstating the need for pathogenetic treatment methods in phthisiology. The practitioner is faced with a difficult choice between the expediency and even necessity of prescribing drugs for pathogenetic therapy and the risk of prescribing drugs whose effectiveness and safety have not been proven. The aim of the work was to familiarize doctors with the principles of prescribing pathogenetic therapy included in the current version of the clinical recommendations “Tuberculosis in adults”. Conclusion. Today, the phthisiological service has drugs of various pharmacological groups in its toolkit that can influence the pathogenesis of tuberculosis and have a high level of evidence from pre-clinical and clinical studies. The new data should be reflected in future versions of the clinical guidelines.
About the Authors
S. V Smerdin
State Budgetary Healthcare Institution of the Moscow Region “Moscow Regional Clinical Tuberculosis Dispensary” ; Moscow Regional Research and Clinical Institute (“MONIKI”)
Russian Federation
Competing Interests:
Russian Federation
Sergey V. Smerdin, Doctor of Medicine, Professor, Chief Physician; Head of the Department of Phthisiology
ul. Dubki 7, pos. Zdravnitsa, Mytishchi, Moscow region, 141132, tel.: (496) 588-41-29
ul. Shchepkina 61/2, Moscow, 129110
Competing Interests:
The authors declare that there is no conflict of interest.
M. V. Vershinina
State Budgetary Healthcare Institution of the Moscow Region “Moscow Regional Clinical Tuberculosis Dispensary” ; Moscow Regional Research and Clinical Institute (“MONIKI”)
Russian Federation
Competing Interests:
Russian Federation
Maria V. Vershinina, Doctor of Medicine, Phthisiologist, Pulmonologist; Professor, Department of Phthisiology
ul. Dubki 7, pos. Zdravnitsa, Mytishchi, Moscow region, 141132, tel.: (496) 588-41-29
ul. Shchepkina 61/2, Moscow, 129110
Competing Interests:
The authors declare that there is no conflict of interest.
M. A. Plekhanova
State Budgetary Healthcare Institution of the Moscow Region “Moscow Regional Clinical Tuberculosis Dispensary” ; Moscow Regional Research and Clinical Institute (“MONIKI”)
Russian Federation
Competing Interests:
Russian Federation
Maria A. Plekhanova, Doctor of Medicine, Deputy Chief Physician for Scientific Work; Professor, Department of Phthisiology
ul. Dubki 7, pos. Zdravnitsa, Mytishchi, Moscow region, 141132, tel.: (496) 588-41-29
ul. Shchepkina 61/2, Moscow, 129110
Competing Interests:
The authors declare that there is no conflict of interest.
References
1. Naumov A.G., Pavlunin A.V. [Mechanisms of development of Mycobacterium tu-berculosis drug resistance: is there a chance to win?]. Pul'monologiya. 2021; 31 (1): 100–108. DOI: 10.18093/0869-0189-2021-31-1-100-108 (in Russian).
2. Smerdin S.V., Vershinina M.V., Plekhanova M.A. [Non-drug therapy of tuberculo-sis: from Chekhov to the present day]. Pul'monologiya. 2025; 35 (3): 423–432. DOI: 10.18093/0869-0189-2025-35-3-423-432 (in Russian).
3. Vasil'eva I.A., Samoylova A.G., Zimina V.N. et al. [Handbook of tuberculosis thera-py in adults]. Мoscow: Meditsinskie znaniya i tekhnologii; 2024. Available at: https://rof-tb.ru/upload/iblock/d39/h9szlc2jo2wj9g0cpjgb93tum7afw7kg.pdf (in Russian).
4. Haitov R.M. [Immunomodulators: myths and reality]. Immunologiya. 2020; 41 (2): 101–106. DOI: 10.33029/0206-4952-2020-41-2-101-106 (in Russian).
5. Balasanyants G.S., Ruzanov D.Ju. [The immunotherapeutic role of interferon-γ in tuberculosis]. Immunologiya. 2022; 43 (3): 343–351. DOI: 10.33029/0206-4952-2022-43-3-343-351 (in Russian).
6. O’Connor G., Gleeson L.E., Fagan-Murphy A. et al. Sharpening nature’s tools for efficient tuberculosis control: a review of the potential role and development of host-directed therapies and strategies for targeted respiratory delivery. Adv. Drug Deliv. Rev. 2016; 102: 33–54. DOI: 10.1016/j.addr.2016.04.024.
7. Ministry of Health of the Russian Federation. [Tuberculosis in adults. Clinical guidelines]. 2024. Available at: https://cr.minzdrav.gov.ru/preview-cr/16_3 [Accessed: May 30, 2025] (in Russian).
8. Ghanavi J., Farnia P., Farnia P., Velayati A.A. The role of interferon-gamma and interferon-gamma receptor in tuberculosis and nontuberculous mycobacterial infections. Int. J. Mycobacteriol. 2021; 10 (4): 349–357. DOI: 10.4103/ijmy.ijmy_186_21.
9. Cooper A.M., Dalton D.K., Stewart T.A. et al. Disseminated tuberculosis in interfer-on gamma gene-disrupted mice. J. Exp. Med., 1993; 178 (6): 2243–2247. DOI: 10.1084/jem.178.6.2243.
10. Master S.S., Rampini S.K., Davis A.S. et al. Mycobacterium tuberculosis prevents inflammasome activation. Cell Host Microbe. 2008; 3 (4): 224–232. DOI: 10.1016/j.chom.2008.03.003.
11. Knoring B.E., Davydova N.I., Shulgina M.V. et al. Features of cytokine profile in pa-tients with progressive TB-induced pulmonary fibrosis characterized by various intensities of pulmonary destructive changes. Prensa Medica Argentina. 2016; 102 (2): 2–11. DOI: 10.4172/lpma.1000201.
12. Vidal. [Handbook of Medicines. Ingaron]. Available at: https://www.vidal.ru/drugs/ingaron__12718 [Accessed: June 05, 2025] (in Russian).
13. Fazly Bazzaz B.S., Seyedi S., Hoseini Goki N., Khameneh B. Human antimicrobial peptides: spectrum, mode of action and resistance mechanisms. Int. J. Pept. Res. Ther. 2021; 27 (Pt 1): 801–816. DOI: 10.1007/s10989-020-10127-2.
14. Steinstraesser L., Kraneburg U., Jacobsen F. Al-Benna S. Host defense peptides and their antimicrobial-immunomodulatory duality. Immunobiology. 2011; 216 (3): 322–333. DOI: 10.1016/j.imbio.2010.07.003.
15. Labarrere C.A., Kassab G.S. Glutathione: a Samsonian life-sustaining small mole-cule that protects against oxidative stress, ageing and damaging inflammation. Front. Nutr. 2002; 9: 1007816. DOI: 10.3389/fnut.2022.1007816.
16. Studentsov E.P., Ramsh S.M., Kazurova N.G. et al. [Adaptogens and related groups of drugs – 50 years of searching]. Obzory po klinicheskoy farmakologii i le-karstvennoy terapii. 2013; 11 (4): 3–43. DOI: 10.17816/RCF1143-43 (in Russian).
17. [Instructions for medical use of the drug glutoxim]. Available at: https://glutoxim.ru/files/instrukciya_glutoksim_novyy_variant.pdf [Accessed: June 05, 2025] (in Russian).
18. Manicheva O.A., Solov'eva N.S., Antonov V.G. et al. [The effect of glutoxim on the antimycobacterial activity of isoniazid against drug-resistant strains of Mycobacterium tu-berculosis]. Tuberkulez i bolezni legkikh. 2014; (9): 89–96. DOI: 10.21292/2075-1230-2014-0-9-20-25 (in Russian).
19. Sinicyn M.V., Bogadel'nikova I.V., Perel'man M.I. [Glutoxim – 10 years in phthisiol-ogy (experience in the treatment of tuberculosis)]. Tuberkulez i bolezni legkikh. 2010; (11): 3–9 (in Russian).
20. Rakisheva Zh.K., Balasanyants G.S., Solov'eva N.S. [Treatment of patients with isoniazid-resistant pulmonary tuberculosis using adjuvant therapy]. Pul'monologiya. 2019; 29 (4): 443–447. DOI: 10.18093/0869-0189-2019-29-4-443-447 (in Russian).
21. Lovacheva O.V., Chernichenko N.V., Evgushhenko G.V. et al. [The results of the use of surfactant in the complex therapy of patients with destructive pulmonary tubercu-losis]. Problemy tuberkuleza i bolezney legkikh. 2006; (10): 12–17 (in Russian).
22. Romanova L.K. [The lungs are an immune organ]. In: Erokhin V.V., Romanova L.K., eds. [Cellular biology of the lungs in normal and pathological conditions. A guide for doctors]. Moscow: Meditsina; 2000: 253–269 (in Russian).
23. Erohin V.V., Lepeha L.N., Erohina M.V., Lovacheva O.V. [The surfactant system in pulmonary tuberculosis]. Moscow: FGBU “TsNIIT” RAMN; 2013. Available at: https://istina.msu.ru/media/publications/book/fa1/62c/8046679/Surfaktantnaya_sistema_pri_tuberkulyoze_lyogkih.pdf (in Russian).
24. Rozenberg O.A., Danilov L.N., Volchkov V.A. et al. [Pharmacological properties and therapeutic activity of domestic pulmonary surfactant preparations]. Byulleten' eksperi-mental'noy biologii i meditsiny.1998; 126 (10): 455–458. Available at: https://www.biosurf.ru/upload/iblock/549/549b47d36c944534286194a010a8a1ab.pdf (in Russian).
25. Timakova Yu.I., Plekhanova M.A., Chiginok N.V. et al. [Possibilities of using pul-monary surfactant in the complex therapy of patients with tuberculosis of the respiratory system: results of a prospective comparative study]. Tuberkulez i bolezni legkikh. 2024; 102 (4): 70–77. DOI: 10.58838/2075-1230-2024-102-4-70-77 (in Russian).
26. [Instructions for the use of the medical drug surfactant-BL]. Available at: https://biosurf.ru/upload/iblock/6e4/6e49442c12cc760f9bbd2d0f5e0ec5a4.pdf?ysclid=mbjjlr2ezo337535441 [Accessed: June 05, 2025] (in Russian).
Supplementary files
Review
For citations:
Smerdin S.V., Vershinina M.V., Plekhanova M.A. Modern capaibilities of pathogenetic drug therapy of tuberculosis. PULMONOLOGIYA. 2025;35(5):714-722. (In Russ.) https://doi.org/10.18093/0869-0189-2025-35-5-714-722
Views:
29
Email this article 